Relevare Pharmaceuticals

Relevare Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel small molecule therapies for chronic pain and respiratory conditions. The company's lead program, RL-101, is a potent and selective TRPA1 antagonist originally licensed from Glenmark Pharmaceuticals. RL-101 is being evaluated for the treatment of diabetic peripheral neuropathy and chronic cough, targeting the underlying mechanisms of sensory nerve activation. Relevare aims to address significant unmet needs in the management of neuropathic pain and inflammatory airway diseases through its specialized focus on TRP channel modulation.